Return

Research groups

Pharmacological targets in inflammation and metabolic diseases

2017 provisional vazquez

Coordinator: Manuel Vázquez

Activation of PPARdelta has been proposed as a therapeutic target to prevent metabolic diseases with an inflammatory basis, such as insulin resistance and type 2 diabetes mellitus. However, the putative molecular mechanisms by which PPARdelta activation might be used to prevent or treat these pathologies remain to be established. We thus aim to examine the effects of PPARdelta activators on hyperinsulinemia and inflammation caused by enhanced plasma free fatty acids, cytokines or advanced glycation endproducts in cellular and animal models of insulin resistance. In addition, we are interested in the link between hyperinsulinemia, inflammation and Alzhimer's disease and the potential role of PPARdelta.

Team

  • Researcher: F. Xavier Palomer Tarridas
  • Postdoc – associate researcher: Emma Barroso Fernández, Javier Pizarro Delgado, Lucía Peña Moreno
  • PhD Student: Gaia Botteri, Mohammad Zarei, Marta Montori Grau, María Silvia Román Azcona

Selected projects

  • Inflamación, resistencia a la insulina y cardiomiopatía diabética: evaluación de los agonistas PPARbeta/delta y del ácido oleico. Ministerio de Economia y Competitividad. PI: Manuel Vázquez Carrera. January 2016 – December 2018
  • Diabetic cardiomyopathy: searching for a therapeutic target. Fundació La Marató de TV3. PI: Manuel Vázquez Carrera. January 2016 – December 2018
  • Dianes farmacològiques en inflamació i malalties metabòliques. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). PI: Manuel Vázquez Carrera.  January 2014 – April 2017
  • Diabetes y enfermedades metabólicas. Ministerio de Sanidad y Consumo. PI: Manuel Vázquez Carrera. October 2007 – December 2017

Selected publications in 2016

  • Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARß/d.. Prog Lipid Res 2016. 64: 98-122. FI: 11,238(Q1)
  • Vázquez-Carrera M. Unraveling the Effects of PPARß/d on Insulin Resistance and Cardiovascular Disease.. Trends Endocrinol Metab 2016. 27: 319-334. FI: 8,964(Q1)
  • Zarei M, Barroso E, Leiva R, Barniol-Xicota M, Pujol E, Escolano C, Vázquez S, Palomer X, Pardo V, González-Rodríguez Á, Valverde ÁM, Quesada-López T, Villarroya F, Wahli W, Vázquez-Carrera M. Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency. Diabetes. 2016 Oct;65(10):3185-99.
  • Palomer X, Barroso E, Zarei M, Botteri G, Vázquez-Carrera M. PPARß/d and lipid metabolism in the heart.. Biochim Biophys Acta 2016. 1860: 1569-1578. FI: 3,016(Q2)